Akeso Reports FY Results
BeiGene Secures Positive CHMP Opinion For TEVIMBRA As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer
AKESO: The sharp decline in commercialization licensing revenue has led to a shift from profit to loss, while sales of Innovative Drugs continue to grow rapidly | Interpretations
① Due to a significant decrease in commercial revenue, AKESO is expected to turn from profit to loss in 2024. ② The commercialization of Innovative Drugs is continuously being promoted, and sales revenue is maintaining rapid growth.
JUNSHI BIO 2024 annual report: Sales of core product PD-1 continue to increase, and the debt-to-asset ratio rises year by year.
In 2024, Tuoyi achieved domestic market sales revenue of 1.501 billion yuan, an increase of approximately 66% year-on-year; From 2022 to 2024, JUNSHI BIO's Cash flow was 4.715 billion yuan, 3.039 billion yuan, and 2.487 billion yuan respectively, showing a decrease in cash flow year by year; During the same period, the debt-to-asset ratios were 22.15%, 35.46%, and 44.98% respectively, indicating signs of an annual increase.
REMEGEN's 2024 Earnings Reports: Commercialization accelerates, losses narrow, and high investment in research and development continues to pressure cash flow.
① In 2024, REMEGEN achieved revenue of 1.415 billion yuan, a year-on-year increase of 58.5%; the annual net loss attributable to the parent company was 1.468 billion yuan, a reduction in loss of 2.84% compared to the previous year; ② Long-term high research and development has placed significant cash flow pressure on REMEGEN.
Zai Lab Shares Are Trading Higher on Possible Continued Strength After the Company Announced Yesterday That It Will Present New Data for Oncology Candidates at the Upcoming Annual 2025 American Association For Cancer Research. Additionally, Cantor...